Literature DB >> 12771723

Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.

Allan J Pantuck1, Amnon Zisman, Fredrick Dorey, Debby H Chao, Ken-Ryu Han, Jonathan Said, Barbara J Gitlitz, Robert A Figlin, Arie S Belldegrun.   

Abstract

PURPOSE: We better defined the benefits and morbidity of lymph node dissection in patients with localized renal cell carcinoma using the experience of patients treated at our institution.
MATERIALS AND METHODS: A retrospective cohort study was performed with outcome assessment based on the chart review of demographic, clinical and pathological data in 1,087 patients with renal cell carcinoma treated at our institution. Patients with renal cell carcinoma who did not undergo nephrectomy as part of cancer treatment, those with bilateral disease and those for whom nodal status was unknown were not included in this study. A total of 900 patients meeting these criteria who underwent nephrectomy for unilateral renal cell carcinoma at our medical center form the principal study population.
RESULTS: Positive lymph nodes were associated with larger, higher grade, locally advanced primary tumors that were more commonly associated with sarcomatoid features. Positive nodes were 3 to 4 times more common in patients with metastatic disease and the majority of these patients could be identified preoperatively. The survival of patients with regional lymph node involvement only was identical to that of patients with distant metastatic disease only. Patients with regional nodes and distant metastases had significantly inferior survival to those with either condition alone. In node negative cases lymph node dissection can be performed with no additional morbidity but it confers no survival advantage. In node positive cases lymph node dissection can also be performed safely but it is associated with improved survival and a trend toward an improved response to immunotherapy.
CONCLUSIONS: Regional lymph node dissection is unnecessary in patients with clinically negative lymph nodes since it offers extremely limited staging information and no benefit in terms of decreasing disease recurrence or improving survival. In patients with positive lymph nodes lymph node dissection is associated with improved survival when it is performed in carefully selected patients undergoing cytoreductive nephrectomy and postoperative immunotherapy. When lymph nodes are present, they should be resected when technically feasible.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771723     DOI: 10.1097/01.ju.0000066130.27119.1c

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  64 in total

1.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 2.  [Therapy strategies for advanced renal cell carcinoma].

Authors:  M Staehler; N Haseke; G Schöppler; T Stadler; C Adam; C G Stief
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

3.  Locally advanced renal cell carcinoma.

Authors:  Mohammed Al Otaibi; Simon Tanguay
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

Review 4.  Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors.

Authors:  Samdeep K Mouli; Lee C Zhao; Reed A Omary; C Shad Thaxton
Journal:  Nat Rev Urol       Date:  2010-01-19       Impact factor: 14.432

5.  Analysis of lymph node dissection in patients with ≥7-cm renal tumors.

Authors:  Michael A Feuerstein; Matthew Kent; Wassim M Bazzi; Melanie Bernstein; Paul Russo
Journal:  World J Urol       Date:  2014-01-09       Impact factor: 4.226

Review 6.  The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence?

Authors:  Karim Bensalah; Morgan Roupret; Evanguelos Xylinas; Shahrokh Shariat
Journal:  World J Urol       Date:  2013-04-16       Impact factor: 4.226

7.  Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.

Authors:  Benjamin T Ristau; Judi Manola; Naomi B Haas; Daniel Y C Heng; Edward M Messing; Christopher G Wood; Christopher J Kane; Robert S DiPaola; Robert G Uzzo
Journal:  J Urol       Date:  2017-07-18       Impact factor: 7.450

8.  Should patients undergoing surgery for renal cell carcinoma have a lymph node dissection?

Authors:  Stephen H Culp; Christopher G Wood
Journal:  Nat Clin Pract Urol       Date:  2009-02-10

9.  Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.

Authors:  Juan Chipollini; E Jason Abel; Charles C Peyton; David C Boulware; Jose A Karam; Vitaly Margulis; Viraj A Master; Kamran Zargar-Shoshtari; Surena F Matin; Wade J Sexton; Jay D Raman; Christopher G Wood; Philippe E Spiess
Journal:  Clin Genitourin Cancer       Date:  2017-10-17       Impact factor: 2.872

10.  Staging of renal cell carcinoma: Current concepts.

Authors:  John S Lam; Tobias Klatte; Alberto Breda
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.